Furthermore, it has been demonstrated that loss of heterozygosity (LOH) at the B2M locus occurred three times more frequently in non-responders than in responders, and loss of both copies of B2M was found only in non-responders among patients with melanoma treated with anti-PD-1 [62]. The gene discussed is B2M; the disease is melanoma.